Merck & Co. unveiled the much-anticipated first look at its PD-1xVEGF bispecific data. China's Zai Lab is looking to go ...
New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and tumor microenvironment while enhancing the systemic tolerability profile Head-to-head ...
While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 ...
Add Yahoo as a preferred source to see more of our stories on Google. Roche has announced data from the open-label extension part of its Phase II trial of the BTK inhibitor. Image credit: Shutterstock ...
We're going to get started. Thank you, everyone, for joining us here in Berlin, and there are many more of you that are online. Welcome to the solid tumor update that we're having at ESMO 2025. We're ...
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus ...
- Mini oral presentation to highlight initial Phase 1 data of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, in patients with advanced or metastatic solid tumors - Oral presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results